A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed
Clinical trial NCT03463369 · COMPLETED
Trial details
- NCT number
- NCT03463369
- Sponsor
- Janssen Sciences Ireland UC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-18
- Primary completion
- 2021-03-23
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.